Stock is over 90 again

Quote






The current price is a buying opportunity and offers a lot more upside potential than competitors. This is a short term corrective trend that should resolve decisively by mid-month
 












anonymous said:
The current price is a buying opportunity and offers a lot more upside potential than competitors. This is a short term corrective trend that should resolve decisively by mid-month
Click to expand...

I wish I was optimistic that our latest ‘engineered’ turnaround strategy is a short term corrective trend. Taking a look at our current BO lead time, that’s at least another full FY (or more) away from achieving our deliverables; and that’s without further distractions such as additional recalls, FDA warnings.
Stock is going to stall for a long period…..
 






anonymous said:
The current price is a buying opportunity and offers a lot more upside potential than competitors. This is a short term corrective trend that should resolve decisively by mid-month
Click to expand...

Week of Action for Equity will drive that price right back up.

Ship has sailed. Time for new leadership. Mission is lost, there's no playbook, every leader is looking for the next "headwind" to blame for bad results.
 


















How does Geoff still have a job? Every shareholder should be revolting with how he has killed the stock and the credibility of the company. Maybe he needs to add a few more DEI execs. What a bleeping failure!!
 


















I’d argue the industry has taken the current technological offerings for pacers/ICDs as far as they will go and everyone is left with a commodity business. Hospitals will continue to demand lower prices for devices as there are several manufacturers available. Physicans are now generally made to implant the manufacturer dictated by the hospital contract. So technology is not driving purchasing decisions by the main customer-the hospitals.
Currently there is nothing unique to any of these companies in this industry anymore. All that is teased in investor meetings is robotic surgery solutions which is not what the company (MDT) knows or specializes in. The stock peaked at $133 as the Micra leadless pacemaker enjoyed market exclusivity and as a new ICD (Cobalt) was launched. Leadless pacemaker tech has since been matched by others in the industry and the Cobalt is riddled with major customer communications/FCAs/recalls and advisories that lead MDT to provide recommendations on programming to mitigate risks to patients. Investors are aware of the cash flow problems. There is nothing exciting going on in the company, no promising technology, no interesting press announcements. The industry and Wall Street did respect Omar. The current stock price reflects the complete lack of enthusiasm there is for this once innovative company. They might innovate their way out of it but will probably seek to expand indications for their devices. That will lead to more patients for the industry just not necessarily more patients for MDT.
 






BoardWithYou said:
I’d argue the industry has taken the current technological offerings for pacers/ICDs as far as they will go and everyone is left with a commodity business. Hospitals will continue to demand lower prices for devices as there are several manufacturers available. Physicans are now generally made to implant the manufacturer dictated by the hospital contract. So technology is not driving purchasing decisions by the main customer-the hospitals.
Currently there is nothing unique to any of these companies in this industry anymore. All that is teased in investor meetings is robotic surgery solutions which is not what the company (MDT) knows or specializes in. The stock peaked at $133 as the Micra leadless pacemaker enjoyed market exclusivity and as a new ICD (Cobalt) was launched. Leadless pacemaker tech has since been matched by others in the industry and the Cobalt is riddled with major customer communications/FCAs/recalls and advisories that lead MDT to provide recommendations on programming to mitigate risks to patients. Investors are aware of the cash flow problems. There is nothing exciting going on in the company, no promising technology, no interesting press announcements. The industry and Wall Street did respect Omar. The current stock price reflects the complete lack of enthusiasm there is for this once innovative company. They might innovate their way out of it but will probably seek to expand indications for their devices. That will lead to more patients for the industry just not necessarily more patients for MDT.
Click to expand...
 


















Stock up 3% today. Rising like a Phoenix from the ashes.

All this noise is bcoz of GLP-1 drugs. All medical device company stocks are down. Nothing medtronic related. BD dropped like 10% just like week
 






Here is a great example of why the stock price is what it is-read the renal denervation study results. At 4 years 15% vs 14% vs 14%. Over a billion of sunk cost into this study and it shows no benefit to patients at 4 years. Also note the size of the study. That’s the best the worlds largest device manufacturer can do? See any data in any of the press releases? The studies are easy to find on google and are luckluster at best! Doctors will understand this data and ignore the press release. What a stock price! Thanks!

The rate of the composite safety endpoint to 48 months, including all-cause death, new-onset end-stage renal disease, significant embolic event resulting in end-organ damage, vascular complication, renal artery re-intervention, and hypertensive emergency was 15% (54 of 352 patients) for the renal artery denervation group, 14% (13 of 96 patients) for the crossover group, and 14% (10 of 69 patients) for the non-crossover group.
 






We know we are best marketeers. We will market products that dont work because some will buy. Hugo is in this camo too. Its sad this is where we are from being the best in the industry. It will be marketed next week by GM but will further hurt our credibility.
 












Hahaha and it’s $80 today!

Boston Scientific is the better company.

Geoff sucks! The whole company sucks. All their ICDs since 2017 are under recall.

There’s your stock price.

And they are bringing back Rick Darr! Wow, that’ll help! Dummies.
 






One year later….what does the company shill think of their post now?

Still such a loser of a stock

If you haven’t been shorting it over the past year you’ve lost your money
 






Top Bottom
Back
Quote